Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2023-08-25 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于召开2023年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice for convening the 2023 second extraordinary general meeting of shareholders of Tianjin Ringpu Biotechnology Co., Ltd. It includes details about the meeting time, location, voting procedures, agenda items, and registration instructions. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. The document length is 4018 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2023-08-25 Chinese
天津瑞普生物技术股份有限公司2022年限制性股票激励计划（草案）摘要（修订稿）
Remuneration Information Classification · 95% confidence The document is a detailed summary draft of a 2022 restricted stock incentive plan by Tianjin Ruipu Biotechnology Co., Ltd. It extensively covers the purpose, scope, management, conditions, accounting treatment, and adjustment procedures of the stock incentive plan. It includes legal references, stock quantities, pricing, vesting conditions, performance targets, and governance related to the incentive plan. The content is focused on the company's stock-based compensation plan for directors, senior management, and key employees. This type of document is a detailed disclosure about a stock incentive plan, which falls under remuneration information related to executive and director compensation. It is not an annual report, earnings release, or a general regulatory filing. It is not a proxy statement or voting result announcement. The document is substantive and lengthy, not a brief announcement or certification. Therefore, the best fitting category is Remuneration Information (DEF 14A).
2023-08-25 Chinese
天津瑞普生物技术股份有限公司2022年限制性股票激励计划实施考核管理办法（修订稿）
Governance Information Classification · 95% confidence The document is titled as a management method for the implementation assessment of a 2022 restricted stock incentive plan by Tianjin Ruipu Biotechnology Co., Ltd. It details the purpose, principles, scope, assessment institutions, performance indicators, assessment periods, procedures, and management of assessment results related to the stock incentive plan. The content focuses on internal governance and performance evaluation related to stock incentives for directors, senior management, and key personnel. There is no financial statement, earnings data, or regulatory filing announcement. The document is a governance-related internal policy document concerning stock incentive plan assessment and management. Therefore, it fits best under Governance Information (CGR) which covers internal rules, board structure, and governance practices.
2023-08-25 Chinese
天津瑞普生物技术股份有限公司2022年限制性股票激励计划（草案）（修订稿）
Board/Management Information Classification · 95% confidence The document is a detailed draft of a 2022 restricted stock incentive plan for Tianjin Ruipu Biotechnology Co., Ltd. It includes comprehensive information about the stock incentive plan, such as the purpose, scope, management, stock source, quantity, allocation, effective period, grant price, conditions for granting and lifting restrictions, performance targets, accounting treatment, and implementation procedures. The document is lengthy (15,000 characters) and contains substantive content about the company's stock incentive plan rather than just an announcement or summary. It is not a financial report like an annual or interim report, nor is it a regulatory filing or announcement. It is a detailed management-level document related to stock-based compensation and incentive plans, which falls under Board/Management Information (MANG) as it relates to management incentives and governance of senior management compensation and stock plans. Therefore, the appropriate classification is MANG with high confidence.
2023-08-25 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "天津瑞普生物技术股份有限公司2023 年半年度报告全文" which translates to "Tianjin Ringpu Biotechnology Co., Ltd. 2023 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company business overview, product descriptions, and operational details for the first half of 2023. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The presence of financial metrics, management analysis, and detailed business segments confirms this is a substantive interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
中国银河证券股份有限公司关于天津瑞普生物技术股份有限公司使用闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from China Galaxy Securities regarding Tianjin Ruipu Biotechnology Co., Ltd.'s use of idle raised funds for cash management. It includes information about the fundraising, investment projects, cash management purpose, limits, risk control, board resolutions, and opinions from independent directors and supervisors. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or voting result. It is a formal audit or verification opinion related to the use of raised funds, which fits the category of an Audit Report / Information (AR). The document is 3868 characters long, which is relatively short but contains substantive verification content rather than just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2023
2023-08-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.